Truvaga

Truvaga sells a single handheld vagus-nerve stimulator priced at $299 (mid-range wellness tech). The device is sold only through the brand’s own website and ships within the United States; no retail partners or subscription add-ons are offered. The product is FDA-cleared as a Class II medical device for acute relief of migraine and episodic cluster headache, distinguishing it from unregulated wellness gadgets. A 2-minute session delivers calibrated electrical pulses through the cervical branch of the vagus nerve, and the company positions the tool as a drug-free, on-demand alternative to injectables or oral meds. Core buyers are adults 25-55 who experience frequent migraines, prefer non-pharmaceutical options, and are comfortable using smartphone-sized tech. The brand appeals to health-conscious consumers who track HRV, biohack, or already use wearables and want portable, evidence-based symptom control. Truvaga competes in the overlapping markets of neuromodulation devices and drug-free migraine relief. It differentiates by offering FDA clearance, prescription-free purchase, pocket-size portability, and a one-time cost rather than a consumable refill model.